1. ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS. (5th November 2018) Authors: Plotkin, Scott; Jordan, Justin; Beauchamp, Roberta; Muzikansky, Alona; Stemmer-Rachamimov, Anat; Ramesh, Vijaya Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA. (5th November 2018) Authors: Beauchamp, Roberta; Erdin, Serkan; Angus, Steven; Stuhlmiller, Timothy; Oblinger, Janet; Jordan, Justin; Haggarty, Stephen J; R. Plotkin, Scott; Chang, Long-Sheng; L. Johnson, Gary; F. Gusella, James; Ramesh, Vijaya Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. (12th November 2021) Authors: Plotkin, Scott; Kumthekar, Priya; Wen, Patrick; Barker, Fred; Beauchamp, Roberta; Gerstner, Elizabeth; Muzikansky, Alona; Smith, Miriam; Stemmer-Rachamimov, Anat; Jordan, Justin; Ramesh, Vijaya Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗